Charles B Brendler
Overview
Explore the profile of Charles B Brendler including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
49
Citations
925
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Conran C, Shi Z, Resurreccion W, Na R, Helfand B, Genova E, et al.
J Transl Med
. 2021 Jan;
19(1):41.
PMID: 33482857
Background: Genome-wide association studies have identified thousands of disease-associated single nucleotide polymorphisms (SNPs). A subset of these SNPs may be additively combined to generate genetic risk scores (GRSs) that confer...
2.
Liu W, Hou J, Petkewicz J, Na R, Wang C, Sun J, et al.
Prostate
. 2020 Aug;
80(14):1253-1262.
PMID: 32803894
Background: To assess the feasibility of a novel DNA-based probe panel to detect copy number alterations (CNAs) in prostate tumor DNA and its performance for predicting clinical progression. Methods: A...
3.
Carter H, Helfand B, Mamawala M, Wu Y, Landis P, Yu H, et al.
Eur Urol
. 2018 Oct;
75(5):743-749.
PMID: 30309687
Background: Mutations in DNA repair genes are associated with aggressive prostate cancer (PCa). Objective: To assess whether germline mutations are associated with grade reclassification (GR) in patients undergoing active surveillance...
4.
Gillard M, Javier R, Ji Y, Zheng S, Xu J, Brendler C, et al.
Cancer Res
. 2018 Sep;
78(21):6134-6145.
PMID: 30181178
Progress in prostate cancer racial disparity research has been hampered by a lack of appropriate research tools and better understanding of the tumor biology. Recent gene expression studies suggest that...
5.
Helfand B, Chen H, Fantus R, Conran C, Brendler C, Zheng S, et al.
Prostate
. 2018 Jun;
PMID: 29923209
Purpose: Family history assigns equivalent risk to all relatives based upon the degree of relationship. Recent genetic studies have identified single nucleotide polymorphisms (SNPs) that can be used to calculate...
6.
Nardi F, Fitchev P, Franco O, Ivanisevic J, Scheibler A, Hayward S, et al.
J Cell Sci
. 2018 May;
131(13).
PMID: 29792311
Prostate tumors make metabolic adaptations to ensure adequate energy and amplify cell cycle regulators, such as centrosomes, to sustain their proliferative capacity. It is not known whether cancer-associated fibroblasts (CAFs)...
7.
Wu Y, Yu H, Zheng S, Na R, Mamawala M, Landis T, et al.
Prostate
. 2018 Mar;
78(8):607-615.
PMID: 29520813
Background: Germline mutations in CHEK2 have been associated with prostate cancer (PCa) risk. Our objective is to examine whether germline pathogenic CHEK2 mutations can differentiate risk of lethal from indolent...
8.
Chen H, Na R, Packiam V, Conran C, Jiang D, Tao S, et al.
Prostate
. 2017 Jul;
77(11):1179-1186.
PMID: 28670847
Background: Although the clinical validity of risk-associated single nucleotide polymorphisms (SNPs) for assessment of disease susceptibility has been consistently established, risk reclassification from increasing numbers of implicated risk-associated SNPs raises...
9.
Na R, Ye D, Qi J, Liu F, Helfand B, Brendler C, et al.
Prostate
. 2017 Jul;
77(11):1221-1229.
PMID: 28664580
Background: The performance of prostate health index (phi) in predicting prostate biopsy outcomes has been well established for patients with prostate-specific antigen (PSA) values between 2 and 10 ng/mL. However,...
10.
Na R, Zheng S, Han M, Yu H, Jiang D, Shah S, et al.
Eur Urol
. 2016 Dec;
71(5):740-747.
PMID: 27989354
Background: Germline mutations in BRCA1/2 and ATM have been associated with prostate cancer (PCa) risk. Objective: To directly assess whether germline mutations in these three genes distinguish lethal from indolent...